{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T12:34:16Z","timestamp":1724416456214},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.neurol.2015.12.004","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T06:47:55Z","timestamp":1456210075000},"page":"220-224","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neuromyelitis optica: Contribution of therapeutic responses markers monitoring in patients given rituximab"],"prefix":"10.1016","volume":"172","author":[{"given":"G.","family":"Romero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ticchioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Rosenthal-Allieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mondot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lebrun Frenay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurol.2015.12.004_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurol.2015.12.004_bib0010","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Zephir","year":"2015","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.neurol.2015.12.004_bib0015","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.12.004_bib0020","first-page":"1","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","author":"Collongues","year":"2015","journal-title":"Mult Scler J"},{"issue":"3","key":"10.1016\/j.neurol.2015.12.004_bib0025","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00415-014-7629-8","article-title":"Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder","volume":"262","author":"Kim","year":"2015","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2015.12.004_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5316\/wjn.v5.i1.39","article-title":"Rituximab in neuromyelitis optica: a review of literature","volume":"5","author":"Wong","year":"2015","journal-title":"World J Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2015.12.004_bib0035","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2015.12.004_bib0040","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jamaneurol.2013.3583","article-title":"Individualized rituximab treatment for neuromyelitis optica spectrum disorders","volume":"70","author":"McKeon","year":"2013","journal-title":"JAMA Neurol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716000114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716000114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T19:51:17Z","timestamp":1536954677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378716000114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0035378716000114"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2015.12.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis optica: Contribution of therapeutic responses markers monitoring in patients given rituximab","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2015.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}